Use of human recombinant growth hormone and human recombinant insulin-like growth factor-l in patients with human immunodeficiency virus infection

Hormone Research in Paediatrics

Volumn 46, Issue 4-5, 1996, Pages 215-221

  Hirschfeld, Steven ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Growth; Growth hormone; HIV; Insulin like growth factor I; Nutrition; Thyroid

Indexed keywords

2',3' DIDEOXYADENOSINE; ANTIVIRUS AGENT; HUMAN GROWTH HORMONE; RECOMBINANT GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

APOPTOSIS; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; ENDOCRINE DISEASE; ENERGY EXPENDITURE; GROWTH DISORDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LEAN BODY WEIGHT; META ANALYSIS; PRIORITY JOURNAL; THYROID DISEASE;

ADULT; BODY COMPOSITION; CHILD; GROWTH DISORDERS; HIV INFECTIONS; HUMAN GROWTH HORMONE; HUMANS; IMMUNITY; INSULIN-LIKE GROWTH FACTOR I; RECOMBINANT PROTEINS;

EID: 0029817192     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000185026     Document Type: Article

References (105)

1. Feingold KR, Krauss RM, Pang M, Docrrler W, Jensen P, Grunfcld C: The hypertriglyceridemia of adquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B, J Clin Endocrinol Metab 1993;76: 1423-1427.
2. Grunfcld C, Pang M, Shimizu L, Shigcnaga JK, Jensen P, Feingold KR: Anorexia, not hypermetabolism, determines weight loss in AIDS, Int Conf AIDS 1991;7:285.
3. Grunfeld C, Kotier DP, Shigcnaga JK, Docrrler W, Timey W, Wang J, Pierson RJ, Feingold KR: Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome, Am J Med 1991:90:154-162.
4. Grunfeld C, Feingold KR: Metabolic disturbances and wasting in the acquired immunodeficiency syndrome, N Engl J Med 1992:327: 329-337.
5. Grunfeld C, Pang M, Docrrler W, Shigcnaga JK, Jensen P, Feingold KR: Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome, J Clin Endocrinol Metab 1992:74:1045-1052.
6. Grunfeld C, Pang MY, Docrrler W, Shigcnaga JK, Kotier DP, Feingold KR: Metabolic disturbances in AIDS: The role of circulating interferon alpha (IFiNa) and tumor necrosis factor (TNF) in the hypertriglyceridemia of AIDS, Inl Conf Aids 1990:6:170.
7. Grunfeld C, Kotier DP, Hamadeh R, Tierney A, Wang J, Pierson RN: Hypertriglyceridemia in the acquired immunodeficiency syndrome, Am J Med 1989;86:27-31.
8. Nonogaki K, Moser AH, Feingold KR, Grunfeld C: Alpha-adrenergic receptors mediate the hypertriglyceridemia induced by endotoxin, but not tumor necrosis factor, in rats, Endocrinology 1994;135:2644-2650.
9. Nonogaki K, Fuller GM, Fuentes NL, Moser AH, Staprans I, Grunfeld C, Feingold KR: lnterleukin-6 stimulates hepatic triglyceride secretion in rats, Endocrinology 1995:136:2143-2149.
10. Grunfeld C, Feingold KR: The role of the cytokines, interferon alpha and tumor necrosis factor in the hypertriglyceridemia and wasting of AIDS, J Nulr 1992:749-753.
11. Hommes MJ, Romijn JA, Enderl E, Sauerwein HP: Resting energy expenditure and substrate oxidation in human immunodeficiency virus (HlV)-infected asymptomatic men: HIV affects host metabolism in the early asymptomatic stage, Am J Clin Nulr 1991:54:311-315.
12. Hellerstein MK, Grunfeld C, Wu K, Christiansen M, Kaempfer S, Kletkc C, Shackleton CH: Increased de novo hepatic lipogencsis in human immunodeficiency virus infection, J Clin Endocrinol Metab 1993:76:559-565.
13. Poral O: The effect of tumor necrosis factor alpha on the activity of lipoprotein lipase in adipose tissue, Lymphokine Res 1989:8:459-469.
14. Melchior JC, Raguin G, Boulier A, Bouvet E, Rigaud D, Matheron S, Casalino E, Vildc JL, Vachon F, Coulaud JP, Apfclbaum M: Resting energy expenditure in human immunodefi-cieney virus-infected patients: Comparison between patients with and without secondary infections, Am J Clin Nutr 1993:57:614-619.
15. Grunfeld C, Pang M, Shimizu L, Shigenaga JK, Jensen P, Feingold KR: Resting energy expenditure, caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome, Am J Clin Nutr 1992:55:455-460.
16. Melchior JC, Salmon D, Rigaud D, Lcport C, Bouvet E, Detruchis P, Vilde JL, Vachon F, Coulaud JP, Apfelbaum M: Resting energy expenditure is increased in stable, malnourished HIV-infected patients, Am J Clin Nutr 1991: 53:437-441.
17. Schwenk A, Hoffcr E, Burger B, Diehl V, Schrappe M: Hypermetabolism in HIV-infected patients - A question of body composition? Nutrition and HIV Int Conf AIDS 1993; 9:77.
18. Vandercam B, Baudoux D, Gillot C, Latcrrc JF, Constant E, Mean A, Demyttenaere E, Roe-seler J, Kolanowski J, Hannique G: Resting energy expenditure (REE) in HIV-infected patients, Int Conf AIDS 1992:8:143.
19. Melchior JD, Salmon D, Rigaud D, Leport C, Vilde JL, Apfelbaum M: Increased energy expenditure and lean body mass in HIV infected patients, Int Conf AIDS 1990:6:169.
20. Anderson R, Grady C, Ropka M: A comparison of calculated energy requirements to measured resting energy expenditure in HIV-1-infected subjects, J Assoc Nurs AIDS Care 1994;5:30-34.
21. Slusarczyk R: The influence of the human immunodeficiency virus on resting energy expenditure, J Acquir Immune Dcfic Syndr 1994:7: 1025-1027.
22. Bell SJ, Chavali S, Baumcr J, Forse RA: Resting energy expenditure, caloric intake, and short-term change in HIV infection and AIDS, J Parentcr Enter Nutr 1993:17:392-394.
23. Hommes MJ, Romijn JA, Godfried MH, Schattcnkerk JK, Buurman WA, Endert E, Sauerwein HP: Increased resting energy expenditure in human immunodeficiency virus-infected men, Metabolism 1990:39:1186-1190.
24. Macallan DC, Noble C, Baldwin C, Jebb SA, Prentice AM, Coward WA, Sawyer MB, McManus TJ, Griffin GE: Energy expenditure and wasting in human immunodeficiency virus infection, N Engl J Med 1995;333:83-88.
25. Todorov P, Caiuk P, McDevitt T, Coles B, Fca-ron K, Tisdale M: Characterization of a cancer cachetic factor, Nature 1996:379:739-742.
26. Wigmore S, Ross J, Falconer JS, Plester CE, Tisdale MJ, Carter DC, Fearon KCH: The effects of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer, Nutrition 1996; 12(suppl):S27-S30.
27. Nair P, Alger L, Hines S, Seiden S, Hebei R, Johnson JP: Maternal and neonatal characteristics associated with HIV infection in infants of seropositive women, J Aequir Immune Defic Syndr 1993;6:298-302.
28. Butz A, Hutton N, Larson E: Immunoglobulins and growth parameters at birth of infants born to HIV seropositive and seronegative women, Am J Public Health 1991;81:1323-1326.
29. Blanche S, Rouzioux C, Moscato ML, Vcbcr F, Mayaux MJ, Jacomet C, Tricoirc J, Deville A, Vial M, Firtion G, de Crepy A, Dovard D, Robin M, Courpotin M, Ciraru-Vigneron N, Le Deist F, Griscelli C: A prospective study of infants born to women seropositive for human immunodeficiency virus type 1, N Engl J Med 1989:320:1643-1648.
30. Bhushan V, Bamji M, Matheson P: Diminished head circumference (HC) in perinatal HIV-1 infection, Int Conf AIDS 1993:9:307.
31. Matheson PB, Abrams EJ: Newborn characteristics in children bom to women at risk for HIV infection, Int Conf AIDS 1992;8:C284.
32. Accng E, Ndugwa C, Marum I., Sscrunjogi L, Lemma M, Guay I., Ball P, Olness K: Early stunting in a cohort of HIV-1 infected children in Uganda, Int Conf AIDS 1992;8:B196.
33. Miller TL, Evans SJ, Orav EJ, Morris V, McIntosh K, Winter HS: Growth and body composition in children infected with the human immunodeficiency virus-1, Am J Clin Nutr 1993; 57:588-592.
34. Alimenti A, Chanoine JP, Spehl M, Levy J: Growth failure in HIV-infected children, Int Conf AIDS 1993:9:307.
35. McKinney RE Jr., Robertson JW: Effect of human immunodeficiency virus infection on the growth of young children, J Pediatr 1993:123: 579-582.
36. McKinney RE, Wilfcrt CM, Katz SL: The effect of human immunodeficiency virus (HIV) infection on the growth of children less than 24 months old, Conf Aids 1992:8:3643.
37. Grunfeld C, Feingold KR: Body weight as essential data in the management of patients with human immunodeficiency virus infection and the acquired immunodeficiency syndrome, Am J Clin Nutr 1993:58:317-318.
38. Palomba E, Matcrazzo P, Ixtla R, Ciuti E, De Sanctis C, Tovo PA: Growth impairment and endocrine dysfunctions in children with HIV-1 infection, Int Conf AIDS I992;8:B200.
39. Boulos R, Rult A, Coberly J, McBrien M, Halsey JD: Effect of maternal HIV status on infant growth and survival, Int Conf AIDS 1994:10: 20.
40. McKinney RE Jr., Wilfert C: Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine, J Pediatr 1994:125:728-733.
41. McKinney RS: Markers prognostic for survival in zidovudine treated, HIV infected children, Pediatr AIDS HIV Infect 1994:5:323.
42. Hcllerstein M, Hoh R, Neese R, Pclfini A, Faix D, Clinton R, Cope F: Effects of nutritional supplements of different composition on nutritional status and gut histology in HIV-wasting: Metabolic abnormalities for prediction of nutrient unrcsponsivity, Int Conf AIDS 1992;8: B207.
43. Ott M, Wcgner A, Caspary WF, Lembcke B: Intestinal absorption and malnutition in patients with the acquired immunodeficiency syndrome (AIDS), Z Gastroenterol 1993:31: 661-665.
44. Kotler DP: Wasting syndrome: nutritional support in HIV infection, AIDS Res Hum Retroviruses 1994:10:931-934.
45. Campelli A, Barabino A, Taverna P, Risso S, Loy A, Jannuzzi C, Bassetti D: Is parenteral nutrition (PN) useful in HIV-infected patients with wasting syndrome (WS)? Int Conf Aids 1992:8:7086.
46. Summerbell CD, Yotile M, McDonald V, Catalan J, Gazzard BG: Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection, Int J S I D AIDS 1992:3:278-280.
47. James JS: Wasting syndrome - Affordable treatments, AIDS Treat News 1995:No 226:6-7.
48. Henderson RA, Saavedra JM, Perman JA, Hutton N, Livingston RA, Yolken RH: Effect of enteral tube feeding on growth of children with symptomatic human immunodeficiency virus infection, J Pediatr Gastroenterol Nutr 1994:18:429-434.
49. Burger B, Schwenk A, Junger H, Ollenschlager G, Wessel D, Diehl V, Schrappe M: Oral supplements in HIV-infected patients with chronic wasting: A prospective trial, Med Klin 1994; 89:579-581,633.
50. Hirschfcld S, Laue L, Cutler G, Pizzo PA: Thyroid abnormalities in children infected with human immunodeficiency virus, J Pediatr 1996:128:70-74.
51. Hommcs MJ, Romijn JA, Endert E, Adriaanse R, Brabant G, Eeftinck SJ, Wiersinga WM, Sauerwein HP: Hypothyroid-like regulation of the pituitary-thyroid axis in stable human immunodeficiency virus infection, Metabolism 1993:42:556-561.
52. LoPresti JS, Fried JC, Spencer CA, Nicoloff JT: Unique alterations of thyroid hormone indices in the acquired immunodeficiency syndrome (AIDS), Ann Intern Med 1989:110: 970-975.
53. Matarazzo P, Palomba E, Lala R, Ciuti E, Altarc F, dcSanctis L, Tovo PA: Growth impairment, IGF 1 hyposccrction and thyroid dysfunction in children with perinatal HIV-1 infection, Acta Paediatr 1994:83:1029-1034.
54. Olivieri A, Sorcini M, Battisti P, Fazzini C, Gilardi E, Sun Y, Medda E, Grandolfo M, Tos-sini G, Natili S, Gioia C, Naraiso P, Visco G, Carta S: Thyroid hvpofunction related with the progression of human immunodeficiency virus infection, J Endocrinol Invest 1993:16:407-413.
55. Raffi E, Brisseau JM, Planchon B, Remi JP, Barrier JH, Grolleau JY: Endocrine function in 98 HIV infected patients: A prospective study, Aids 1991;5:729-733.
56. Coodlcy GO, Loveless MO, Nelson HD, Cood-ley MK: Endocrine function in the HIV wasting syndrome, J Acquir Immune Defic Syndr 1994:7:46-51.
57. Rabkin JG, Rabkin R, Wagner G: Testosterone replacement therapy in HIV illness, Gen Hosp Psychiatry 1995:17:37-42.
58. Mcrcnich JA, McDermott MT, Asp AA, Harrison SM, Kidd GS: Evidence of endocrine involvement early in the course of human immunodeficiency virus infection, J Clin Endocrinol Metab 1990:70:566-571.
59. Bomstein P, Mercado M, Phair J, Murphy R: Human growth hormone (HGH) and insulinlike growth factor-1 (IGF-1) in HIV-infected patients, Int Conf AIDS 1993:9:293.
60. Gcffncr ME, Ych DY, Undaw EM, Scott ML, Stiehm ER, Bryson YJ, Israclc V: in vitro insu-lin-likc growth factor-I, growth hormone, and insulin resistance occurs in symptomatic human immunodeficiency virus-1-infected children, Pediatr Res 1993:34:66-72.
61. Schwartz U, St Louis Y, Wu R, Wiznia A, Rubinstein A, Saenger P: Endocrine function in children with human immunodeficiency virus infection, Am J Dis Child 1991; 145:330-333.
62. Uuc L, Pizzo PA, Butler K, Cutler GB Jr.: Growth and neuroendocrine dysfunction in children with acquired immunodeficiency syndrome, J Pediatr 1990:117:541-545.
63. Lepage P, Van de Pcrrc P, Van Vliet G, Nsen-gumuremyi F, Van Goethen C, Kcstclyn P, Mscllati P, Hitimana DG: Clinical and endo-crinologic manifestations in perinatally human immunodeficiency virus type l-infcctcd children aged 5 years or older, Am J Dis Child 1991:145:1248-1251.
64. Verdon R, Melchior JC, Bouchaud O, Longuct P, Houzc S: Multivariate analysis of risk factors for severe weight loss in AIDS patients, Int Conf AIDS 1993:9:77.
65. McKinney RE Jr, Malta MA, Connor EM, Fcinberg J, Scott GB, Wulfsohn M, McIntosh K, Borkowsky W, Modlin JF, Weintrub P, O'Donnell K, Gclber R, Rogers G, Lchrman S, Wilfcrt C: A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virusdisease, N Engl J Med 1991: 324:1018-1025.
66. Palasanlhiran P, Ziegler JB, Kemp AS, Ekcrt H, Jupe DM, Gatenbv PA, Keller AJ, Smales O: Zidovudine (AZT) therapy in children with HIV infection: The Australian experience, J Paediatr Child Health 1990;26:257-262.
67. Nozyce M, Hoberman M, Arpadi S, Wiznia A, Lambert G, Dobroszycki J, St Louis Y, Caspe W: The effects of oral AZT on ncurodcvclop-mental, immunologic and clinical outcomes in vertically HIV-infected children, Int Conf AIDS 1992;8:B200.
68. Butler K, Husson R, Eddy J, Santacroce S, Jarosinski P, Moss H, Wolters P, El-Amin D, Brouwers P, Wiener L, Balis FM, Poplack D, Pizzo PA: The activity and tolerance of dideox-vinosine (ddl) administered for 24 weeks to symptomatic HIV infected children: A phrase I/II trial, Int Conf AIDS 1990:6:95.
69. Arkins S, Dantzcr R, Kelley KW: Somatolac-togens, somatomcdins, and immunity, J Dairy Sci 1993:76:2437-2450.
70. Barber MC, Clegg RA, Finley E, Vernon RG, Flint DJ: The role of growth hormone, prolactin and insulin-like growth factors in the regulation of rat mammary gland and adipose tissue metabolism during lactation, J Endocrinol 1992;135:195-202.
71. Baxter JB, Blalock JE, Weigent DA: Characterization of immunoreactive insulin-like growth factor-1 from leukocytes and its regulation by growth hormone, Endocrinology 1991:129: 1727-1734.
72. Bcrczi I, Nagy E, de Toledo SM, Matusik RJ, Friescn HG: Pituitary' hormones regulate c-myc and DNA synthesis in lymphoid tissue, J Immunol 1991:146:2201-2206.
73. Edwards CD, Arkins S, Yungcr LM, Blum A, Dantzer R, Kelley KW: The macrophage-activating properties of growth hormone, Cell Mol Neurobiol 1992;12:499-510.
74. Gala RR: Prolactin and growth hormone in the regulation of the immune system, Proc Soc Exp Biol Med 1991:198:513-527.
75. Gcffncr ME, Bcrsch N, Lippe BM, Rosenfeld RG, Hintz RL, Goldc DW: Growth hormone mediates the growth of T-lymphoblast cell lines via locally generated insulin-like growth factor-I, J Clin Endocrinol Metab 1990;71:464-469.
76. Kant GJ, Shih TM, Bcmton EW, Fein HG, Smallridgc RC, Mougev EH: Effects of soman on neuroendocrine and immune function, Ncurotoxicol Teratol 1991; 13:223-228.
77. Roldan A, Charrcau E, Schillaci R, Eugui EM, Allison AC: Insulin-like growth factor-1 increases the milogcnic response of human peripheral blood lymphocytes to phytohemagglutinin, Immunol Lett 1989;20:5-8.
78. Rom WN, Paakko P: Activated alveolar macrophages express the insulin-like growth factor-I receptor, Am J Respir Cell Mol Biol 1991:4: 432-439.
79. Stuan CA, Meehan RT, Neale LS, Cintron NM, Furlanetto RW: Insulin-like growth fac-tor-l binds selectively to human peripheral blood monocytes and B-lvmphocytes, J Clin Endocrinol Metab 1991;72:1117-1122.
80. Wiedcrmann CJ, Niedermuhlbichler M, Gcissler D, Beimpold H, Braunsteiner H: Priming of normal human neutrophils by recombinant human growth hormone, Br J Haematol 1991:78:19-22.
81. Murphy WJ, Durum SK, Longo DL: Human growth hormone promotes engraftntenl of murine or human T cells in severe combined immunodeficient mice, Proc Natl Acad Sci USA 1992:89:4481-4485.
82. Binz K, Jollcr P, Froesch P, Binz H, Zapf J, Frocsch ER: Repopulation of the atrophied thymus in diabetic rats by insulin-like growth factor I, Proc Natl Acad Sci USA 1990:87: 3690-3694.
83. Murphy WJ, Durum SK, Anver MR, Longo DL: Immunologic and hematologic effects of neuroendocrine hormones: Studies on DW/J dwarf mice, J Immunol 1992:148:3799-3805.
84. Ohzcki T, Hanaki K, Motozumi H, Ohlahara H, Hayashibara H, Harada Y, Okamoto M, Shiraki K, Tsuji Y, Emura H: Immunodeficiency with increased immunoglobulin M associated with growth hormone insufficiency, Acta Paediatr 1993;82:620-623.
85. Rapaport R, Olcske J: Immune function during growth hormone therapy, J Pediatr 1990:116: 669-670.
86. Rapaport R, Petersen B, Skuza KA, Heim M, Goldstein S: Immune functions during treatment of growth hormone-deficient children with biosynthetic human growth hormone, Clin Pediatr Phila 1991;30:22-27.
87. Rekers-Mombarg LT, Rijkers GT, Massa GG, Wit JM: Immunologic studies in children with idiopathic short stature before and during growth hormone therapy, Horm Res 1995:44: 203-207.
88. Rongcn WC, Rijkers GT, Scholtens EJ, Van EA, van denWit JM, Brande JI, Zegers BJ: Immunologic studies in Turner syndrome before and during treatment with growth hormone, J Pediatr 1991; 119:268-272.
89. Rubin R, Bascrga R: Insulin-like grow th factor-I receptor: Its role in cell proliferation, apopto-sis, and lumorigenicity, Lab Invest 1995:73: 311-331.
90. Resnicoff M, Burgaud JL, Rotman HL, Abraham D, Bascrga R: Correlation between apo-ptosis, tumorigencsis, and levels of insulin-like growth factor I receptors, Cancer Res 1995:55: 3739-3741.
91. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R, Zoltick P, Bascrga R: The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo, Cancer Res 1995:55:2463-2469.
92. Sell C, Baserga R, Rubin R: Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoplosis, Cancer Res 1995: 55:303-306.
93. Rodriguez Tarduchy G, Collins MK, Garcia I, Lopez Rivas A: Insulin-like growth factor-1 inhibits apoplosis in IL-3-dependem hemopoietic cells, J Immunol 1992,149:535-540.
94. Muta K, Krantz SB: Apoplosis of human ery-throid colony-forming cells is decreased by stem cell factor and insulin-like growth factor I as well as erythropoietin, J Cell Physiol 1993: 156:264-271.
95. Gougcon ML: T cell apoplosis as a consequence of chronic activation of the immune system in HIV infection, Adv Exp Med Biol 1995;374:121-127.
96. Oyaizu N, Pahwa S: Role of apoptosis in HIV disease pathogenesis, J Clin Immunol 1995:15: 217-231.
97. Laurence J, Grintison B, Gonenne A: Effect of recombinant human growth hormone on acute and chronic human immunodeficiency virus infection in vitro, Blood 1992:79:467-472.
98. Nguyen BY, Clerici M, Bauza S, Bailey J, Longo D, Murphy W, Shearer G, Gesundheit N, Broder S, Yarchoan R: A pilot study of recombinant human insulin-like growth hormone (rhlGF-1) and recombinant human growth hormone (rhGH) in patients with HIV-I infections, 1st Natl Conf Hum Retroviruses Relat Infect, 1993;p 74.
99. Koster F, Nightingale S, Gesundheit N, Waters D, Bukar J, Qualls C, Danska J, Watson D, Jackson L, Hardy K, Schade D: A randomized, double blind placebo-controlled phase II trial of growth hormone and insulin-like growth factor 1 for AIDS wasting (abstract), Intersci Conf Antimicrob Agents Chemother 1994;p 16.
100. Bukar JG, Jackson L, Muro J, Jenks BH, Bakst R, Brodsky M, Gesundheit N: Effect of a combination of growth hormone (rhGH) and insulin-like growth factor-1 (rhlGF-l) on the appetite of HIV-1+ patients (PTS) with weight (WT) loss, Int Conf AIDS 1994:10: 222.
101. Liebcrman SA, Butterfield GE, Harrison D, Hoffman AR: Anabolic effects of recombinant insulin-like growth factor-1 in cachectic patients with the acquired immunodeficiency syndrome, J Clin Endocrinol Mctab 1994:78: 404-410.
102. Grunfeld C, Mulligan K, Hcllcrstein M, Schambelan M: Growth hormone therapy promotes positive nitrogen balance and weight gain in AIDS, Int Conf AIDS 1992:8: B230.
103. Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, Schambelan M: Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection, J Clin Endocrinol Metab 1993:77:956-962.
104. Schambelan M, Mulligan K, Grunfeld C, Daar E, Lamarca A, Breitmeycr J: Recombinant human growth hormone (rhGH) increases lean body mass (LBM) and improves functional performance in patients with HIV-associated wasting, 2nd Natl Conf Hum Retroviruses Relat Infect, 1995, p 170.
105. Hirschfeld S, Tudor-Williants G, Stocker V, Jacobsen F, Laue L, Cutler GB, Pizzo PA: Effects of recombinant human growth hormone and recombinant insulin-like growth factor-1 administration in children with human immunodeficiency virus infection and growth failure, 2nd Natl Conf Hum Retroviruses Relat Infect, 1995, p 149.